Bangavax
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | mRNA |
Clinical data | |
Other names | Bancovid |
Routes of administration | Intramuscular |
ATC code |
|
Part of a series on the |
COVID-19 pandemic |
---|
|
|
|
|
COVID-19 portal |
Bangavax, also known as Bancovid, is a COVID-19 vaccine candidate developed by a Bangladeshi pharmaceutical company Globe Biotech Limited.[1][2][3][4][5][6] The vaccine was initially called Bancovid.[7] As of May 2021, Globe Biotech is awaiting for approval to conduct the first clinical trial.
History[edit]
On 2 July 2020, Globe Biotech Limited announced to be the first company from Bangladesh to have a Covid-19 vaccine under development.[1] The lone Bangladeshi company actually developed three COVID-19 vaccine candidates with different technologies.[8] The company named the mRNA based vaccine as Bancovid then renamed to Bangavax.[7] Globe Biotech took all the necessary steps from December 2020 to January 2021 to get the permission for ethical approval to conduct the first clinical trial of Bangavax.[4] However fate of the Bangavax is still uncertain due to a unknown reason. The Bangladesh government has been criticized for not approval the vaccine even after months to conduct the first clinical trial without any explanation.[9]
References[edit]
- ^ a b "Globe Biotech's Covid-19 vaccine 'BANCOVID' listed by WHO". Daily Sun. 17 October 2020. Retrieved 28 April 2021.
- ^ "'Bangavax' to get approval within a week". dailyobserver. 25 April 2021. Retrieved 28 April 2021.
- ^ "Globe Biotech applies for clinical trial". Prothom Alo. 17 January 2021. Retrieved 28 April 2021.
- ^ a b "Globe Biotech yet to get BMRC nod for human trials". Dhaka Tribune. 22 February 2021. Retrieved 28 April 2021.
- ^ "Bangladesh joins global COVID-19 vaccine race with Bongavax set for clinical trial". Arab News. 8 January 2021. Retrieved 28 April 2021.
- ^ "BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response". bioRxiv. Retrieved 28 April 2021.
- ^ a b "Globe Biotech to produce vaccine candidate for clinical trial". The Financial Express. 6 January 2021. Retrieved 28 April 2021.
- ^ "3 Covid-19 vaccine candidates by Bangladesh's Globe Biotech enlisted in WHO draft landscape". The Daily Star. 17 October 2020. Retrieved 4 May 2021.
- ^ "Bangavax first buzzed with hope, then fizzled". bdnews24. 6 May 2021. Retrieved 6 May 2021.
Scholia has a profile for Bangavax (). |
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it. |
This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
- Articles with short description
- Short description with empty Wikidata description
- Use dmy dates from April 2021
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine
- All stub articles